Loncar Cancer Immunotherapy ETF (CNCR)

Overview

The Loncar Cancer Immunotherapy ETF (CNCR) focuses on companies developing cancer immunotherapies, a revolutionary approach to fighting cancer by harnessing the body's immune system. It targets the healthcare sector, primarily allocating assets to biotech and pharmaceutical firms involved in immunotherapy research and development.

Reputation and Reliability

While Loncar Funds was a smaller issuer, its ETFs were eventually acquired by GraniteShares. GraniteShares has a mixed reputation but is generally considered a reliable issuer offering innovative thematic ETFs.

Management Expertise

The management team at GraniteShares has experience in ETF management and thematic investing, though cancer immunotherapy is a specialized field. It is best to investigate the manager's track record and qualifications specifically.

Goal

The primary investment goal of CNCR is to seek long-term capital appreciation by investing in companies engaged in the research, development, and commercialization of cancer immunotherapies.

Investment Approach and Strategy

Strategy: CNCR tracks an index of companies involved in cancer immunotherapy, offering exposure to the broad immunotherapy sector.

Composition CNCR primarily holds stocks of biotechnology and pharmaceutical companies. The ETF rebalances quarterly and weights holdings based on market capitalization, with modifications for specific inclusion criteria related to cancer immunotherapy involvement.

Market Share: CNCR's market share within the cancer-related or thematic biotech ETF space is relatively small.

Total Net Assets (AUM): 14000000

Key Competitors

• IBB
• XBI
• ARKG
• PJP
• FBT
• XLV

Competitive Landscape

The ETF industry is fiercely competitive. CNCR faces competition from broad biotech ETFs like IBB and XBI, as well as innovation-focused ETFs like ARKG. CNCR offers a more targeted focus on cancer immunotherapy, potentially leading to higher growth if the sector performs well. However, its smaller size and higher expense ratio can be disadvantages compared to larger, more diversified ETFs.

Historical Performance: Historical performance data needs to be analyzed from credible sources. Performance figures include annual returns for the past 1, 3, 5, and 10 years (if available), and since inception.

Benchmark Comparison: CNCR's performance should be compared to the S&P 500 and a relevant biotech or healthcare index (e.g., IBB or XBI) to assess its relative performance.

Expense Ratio: 0.79

Average Trading Volume

Average trading volume for CNCR is relatively low, potentially indicating lower liquidity than more popular ETFs.

Bid-Ask Spread

The bid-ask spread can vary but is usually wider for CNCR than for more liquid ETFs due to its smaller trading volume.

Market Environment Factors

Market dynamics are affected by factors such as biotech industry growth, regulatory changes in healthcare, clinical trial successes/failures, and overall market sentiment towards innovative therapies. The current bullish or bearish condition of the market, interest rate changes, and inflation rates also affect the market.

Growth Trajectory

The growth trajectory of CNCR depends on the success of cancer immunotherapy research and development. Any changes in the ETF's strategy or holdings would reflect the evolving landscape of the immunotherapy sector.

Competitive Edge

CNCR's competitive edge lies in its targeted focus on cancer immunotherapy, providing investors pure-play exposure to this high-growth area within healthcare. This specialization allows investors to capitalize on advances in immunotherapy research without the dilution of exposure to other segments of the healthcare industry. Its smaller asset base, while currently a disadvantage, offers the potential for significant percentage growth if immunotherapy gains further traction. The Loncar name was also well known for cancer immunotherapy research.

Volatility

CNCR is expected to exhibit higher volatility than broad market ETFs due to its focus on the biotechnology sector and the inherent risks associated with pharmaceutical development. Historical volatility (Beta) should be considered.

Market Risk

Specific risks include regulatory hurdles, clinical trial failures, competition from other therapies, and the financial stability of smaller biotech companies within the portfolio. Market risks may be amplified due to the specific focus of this fund.

Ideal Investor Profile

The ideal investor for CNCR is someone with a high-risk tolerance, a long-term investment horizon, and a strong belief in the potential of cancer immunotherapy. They should be comfortable with the volatility associated with investing in a specialized sector.

Market Risk

CNCR is best suited for long-term investors willing to accept higher risk in exchange for potentially higher returns. It's not generally recommended for risk-averse investors or those seeking passive index-tracking strategies.

The Loncar Cancer Immunotherapy ETF (CNCR) provides focused exposure to companies pioneering cancer immunotherapy. While it offers potential for high growth, it also carries higher risk due to its specialized nature and small asset base. Investors should carefully weigh its potential rewards against the inherent volatility and sector-specific risks before investing. CNCR may be a suitable addition to a diversified portfolio for investors who are bullish on cancer immunotherapy and understand its unique characteristics. Due to the sector-specific exposure and market conditions, the investor should be aware of the potential risks before taking a position.

• IBB
• XBI
• ARKG
• PJP
• FBT
• XLV
• ONCO

Data Sources:

• ETF.com
• GraniteShares
• Morningstar
• Yahoo Finance
• Company Filings

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and after consulting with a qualified financial advisor. Past performance is not indicative of future results. Market share data is estimated and may vary.